Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 7, Pages 1564-1570
Publisher
Springer Nature
Online
2015-02-17
DOI
10.1038/leu.2015.43
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
- (2014) D. W. Scott et al. BLOOD
- Numerical and Structural Genomic Aberrations Are Reliably Detectable in Tissue Microarrays of Formalin-Fixed Paraffin-Embedded Tumor Samples by Fluorescence In-Situ Hybridization
- (2014) Heike Horn et al. PLoS One
- Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens
- (2013) N. Masque-Soler et al. BLOOD
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
- (2013) H. Horn et al. BLOOD
- Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
- (2013) R. Coutinho et al. CLINICAL CANCER RESEARCH
- MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
- (2013) A. Valera et al. HAEMATOLOGICA
- Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
- (2013) Alexandar Tzankov et al. MODERN PATHOLOGY
- Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma
- (2012) W. Klapper et al. BLOOD
- Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
- (2012) C. Visco et al. HAEMATOLOGICA
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
- (2012) Norbert Schmitz et al. LANCET ONCOLOGY
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
- (2011) G. Salles et al. BLOOD
- Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
- (2011) Nalan Akyurek et al. CANCER
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
- (2010) G. Ott et al. BLOOD
- Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
- (2010) Sharon Barrans et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic aberrations in paediatric acute leukaemias and implications for management of patients
- (2010) Tomasz Szczepański et al. LANCET ONCOLOGY
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
- (2009) K. J. Savage et al. BLOOD
- A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
- (2009) W. W.L. Choi et al. CLINICAL CANCER RESEARCH
- Pediatric follicular lymphoma - a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials
- (2009) I. Oschlies et al. HAEMATOLOGICA
- Immuno–Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
- (2009) Christiane Copie-Bergman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
- (2009) Heidi Nyman et al. MODERN PATHOLOGY
- Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols
- (2008) D. de Jong et al. HAEMATOLOGICA
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now